Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ptc Therapeutics (PTCT) FCF Margin (2016 - 2025)

Ptc Therapeutics (PTCT) has 14 years of FCF Margin data on record, last reported at 22.25% in Q4 2025.

  • For Q4 2025, FCF Margin fell 943.0% year-over-year to 22.25%; the TTM value through Dec 2025 reached 40.58%, up 6687.0%, while the annual FY2025 figure was 40.58%, 5394.0% up from the prior year.
  • FCF Margin reached 22.25% in Q4 2025 per PTCT's latest filing, up from 33.05% in the prior quarter.
  • Across five years, FCF Margin topped out at 73.84% in Q1 2025 and bottomed at 104.28% in Q4 2022.
  • Average FCF Margin over 5 years is 26.34%, with a median of 33.2% recorded in 2025.
  • Peak YoY movement for FCF Margin: tumbled -10782bps in 2021, then surged 6981bps in 2023.
  • A 5-year view of FCF Margin shows it stood at 46.94% in 2021, then crashed by -122bps to 104.28% in 2022, then skyrocketed by 67bps to 34.47% in 2023, then soared by 63bps to 12.82% in 2024, then plummeted by -74bps to 22.25% in 2025.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 22.25% in Q4 2025, 33.05% in Q3 2025, and 33.35% in Q2 2025.